RxDoctor Payments Data

Thomas Ogara, MD

Family Medicine · Reno, NVNPI 1841287026

Payments from drug & device makers

$7,148in general payments, 2019–2025

Across 487 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Esperion Therapeutics, Inc.$865
  • GSK$560
  • Astellas Pharma US Inc$436
  • Pfizer$406
  • Boehringer Ingelheim$397
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,01898%
  • Education$1302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,148 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$197,295
Medicare patients
552
Services billed
2,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$161,406
EliquisApixaban117$93,816
MounjaroTirzepatide70$84,903
TrulicityDulaglutide30$56,320
XareltoRivaroxaban51$47,593
JardianceEmpagliflozin45$46,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$46,221
JanuviaSitagliptin Phosphate22$31,268
Breo ElliptaFluticasone/Vilanterol45$27,627
FarxigaDapagliflozin Propanediol29$22,720
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,751
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$12,854
Lantus SolostarInsulin Glargine,hum.Rec.Anlog100$11,957
LinzessLinaclotide20$11,499
MyrbetriqMirabegron18$11,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$161,406150 claims
Lilly USA, LLCMounjaro, Trulicity$101$141,223100 claims
PfizerEliquis$406$93,816117 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$560$85,205143 claims
Boehringer IngelheimJardiance, Combivent Respimat$397$51,85756 claims
Johnson & JohnsonXarelto$205$47,59351 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$78$43,32365 claims
MerckJanuvia$84$31,26822 claims
AbbVieLinzess, Synthroid$1,743$17,87891 claims
Astellas Pharma US IncMyrbetriq$436$11,46218 claims
Esperion Therapeutics, Inc.Nexlizet$865$6,26113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →